Shareholder alert: monteverde & associates pc announces an investigation of adamas pharmaceuticals, inc. - adms

New york, oct. 15, 2021 /prnewswire/ -- juan monteverde , founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018-2020 iss securities class action services report and headquartered at the empire state building in new york city, is investigating adamas pharmaceuticals, inc. ("adms" or the "company") (adms) relating to its proposed acquisition by supernus pharmaceuticals, inc. under the terms of the agreement, adms shareholders will receive $8.10 plus two contingent value rights collective worth $1.00 in cash per share they own. the investigation focuses on whether adamas pharmaceuticals, inc. and its board of directors violated securities laws and/or breached their fiduciary duties to the company by 1) failing to conduct a fair process, and 2) whether the transaction is properly valued.
ADMS Ratings Summary
ADMS Quant Ranking